Wilms' tumor 1 gene (WT1) is overexpressed and provides an oncogenic function in pediatric nephroblastomas harboring the wild-type WT1

Sangkhathat,Surasak; Kanngurn,Samornmas; Chaiyapan,Welawee; Gridist,Podchanaporn; Maneechay,Wanwisa

doi:10.3892/ol_00000109

Wilms' tumor 1 gene (WT1) is overexpressed and provides an oncogenic function in pediatric nephroblastomas harboring the wild-type WT1

Authors:
- Surasak Sangkhathat
- Samornmas Kanngurn
- Welawee Chaiyapan
- Podchanaporn Gridist
- Wanwisa Maneechay
View Affiliations

Affiliations: Tumor Biology Research Unit, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand. surasak.sa@psu.ac.th
Published online on: July 1, 2010 https://doi.org/10.3892/ol_00000109
Pages: 615-619

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Wilms' tumor 1 gene (WT1) is known to be a tumor suppressor gene in the subset of nephroblastomas that harbors WT1 mutations. However, its role in nephroblastomas without mutations remains unclear. This study aimed to evaluate the expression of WT1 and its potential oncogenic role in pediatric nephroblastoma with wild-type WT1. A total of 24 nephroblastomas were studied for WT1 mRNA expression by quantitative reverse-transcription polymerase chain reaction. The expression levels were compared between nephro-blastomas with and without WT1 mutations, as well as to normal kidney tissue, other pediatric renal tumors and neuroblastomas. Immunohistochemistry was used to evaluate expression patterns at the tissue level. Post-transcriptional inhibition of WT1 was performed in primary cultures of wild-type nephroblastoma using WT1 siRNA. The average WT1 expression level in nephroblastoma tissue was significantly higher than that in normal kidney tissue and neuroblastomas. Expression at the mRNA level was not different between nephroblastomas with WT1 mutations (4 cases) and those with wild-type WT1 (20 cases). However, while WT1 immunoreactivity was positive in all of the nephroblastoma components in the tumors with wild-type WT1, the protein expression was weaker and limited to stromal components in the tumors with mutated WT1, where it co-localized with β-catenin nuclear accumulation. The post-transcriptional inhibition of WT1 resulted in growth retardation and a significantly increased apoptotic fraction. Our study found overexpression of the WT1 gene in pediatric nephroblastomas with wild-type WT1. Moreover, the study suggests an oncogenic role of WT1 in this tumor subset.

View Figures

View References

1	Beckwith JB, Kiviat NB and Bonadio JF: Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms’ tumor. Pediatr Pathol. 10:1–36. 1990.
2	Li CM, Kim CE, Margolin AA, et al: CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms’ tumors. Am J Pathol. 165:1943–1953. 2004.PubMed/NCBI
3	Rivera MN, Kim WJ, Wells J, et al: An X chromosome gene, WTX, is commonly inactivated in Wilms tumor. Science. 315:642–645. 2007. View Article : Google Scholar : PubMed/NCBI
4	Perotti D, Gamba B, Sardella M, et al: Functional inactivation of the WTX gene is not a frequent event in Wilms’ tumors. Oncogene. 27:4625–4632. 2008.PubMed/NCBI
5	Lee SB and Haber DA: Wilms tumor and the WT1 gene. Exp Cell Res. 264:74–99. 2001. View Article : Google Scholar : PubMed/NCBI
6	Moore AW, McInnes L, Kreidberg J, Hastie ND and Schedl A: YAC complementation shows a requirement for WT1 in the development of epicardium, adrenal gland and throughout nephrogenesis. Development. 126:1845–1857. 1999.PubMed/NCBI
7	Sangkhathat S, Chotsampancharaen T, Kayasut K, Patrapinyokul S, Chiengkriwate P, Kitichet R and Maipang M: Outcomes of pediatric nephroblastoma in southern Thailand. Asian Pac J Cancer Prev. 9:643–647. 2008.PubMed/NCBI
8	Oji Y, Yamamoto H, Nomura M, et al: Overexpression of the Wilms’ tumor gene WT1 in colorectal adenocarcinoma. Cancer Sci. 94:712–717. 2003.
9	Sangkhathat S, Kusafuka T, Miao J, et al: In vitro RNA interference against β-catenin inhibits the proliferation of pediatric hepatic tumors. Int J Oncol. 28:715–722. 2006.
10	Wanitsuwan W, Kanngurn S, Boonpipattanapong T, Sangthong R and Sangkhathat S: Overall expression of beta-catenin outperforms its nuclear accumulation in predicting outcomes of colorectal cancers. World J Gastroenterol. 14:6052–6059. 2008. View Article : Google Scholar : PubMed/NCBI
11	Navakanit R, Graidist P, Leeanansaksiri W and Dechsukum C: Growth inhibition of breast cancer cell line MCF-7 by siRNA silencing of Wilms tumor 1 gene. J Med Assoc Thai. 90:2416–2421. 2007.PubMed/NCBI
12	Sangkhathat S, Nara K, Kusafuka T, Yoneda A and Fukuzawa M: Artificially accumulated β-catenin inhibits proliferation and induces neurite extension of neuroblastoma cell line NB-1 via up-regulation of trkA. Oncol Rep. 16:1197–1203. 2006.
13	Fukuzawa R, Anaka MR, Weeks RJ, Morison IM and Reeve AE: Canonical WNT signaling determines lineage specificity in Wilms tumour. Oncogene. 28:1063–1075. 2009. View Article : Google Scholar : PubMed/NCBI
14	Fukuzawa R, Heathcott RW, More HE and Reeve AE: Sequential WT1 and CTNNB1 mutations and alterations of beta-catenin localisation in intralobar nephrogenic rests and associated Wilms tumours: two case studies. J Clin Pathol. 60:1013–1016. 2007. View Article : Google Scholar : PubMed/NCBI
15	Fukuzawa R, Heathcott RW, Sano M, Morison IM, Yun K and Reeve AE: Myogenesis in Wilms’ tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway. Pediatr Dev Pathol. 7:125–137. 2004.
16	Hohenstein P and Hastie ND: The many facets of the Wilms’ tumor gene, WT1. Hum Mol Genet. 15:R196–R201. 2006.PubMed/NCBI